Aptatek Biosciences Secures Financing to Advance PheCheck Home-Based PKU Monitoring System
Aptatek Biosciences, Inc., a clinical-stage diagnostics company developing connected technologies for decentralized metabolic monitoring, has announced the initial close of a financing round led by Canterbury Scientific Ltd. and Longview Innovation. Financial terms of the transaction were not disclosed.
The financing is expected to support the clinical evaluation and continued development of PheCheck™, Aptatek’s first application of its HomeCheck™ platform. The investigational diagnostic system is being developed to enable rapid, quantitative measurement of phenylalanine (Phe) in blood at home, with the goal of providing people living with phenylketonuria (PKU) and their healthcare teams with more timely information for disease management.
The financing comes as Aptatek advances PheCheck through clinical development and prepares for a potential regulatory submission to the U.S. Food and Drug Administration (FDA). The company expects to complete its ongoing clinical study before the end of the year and use the resulting data to support a planned FDA regulatory submission.
PheCheck has already received FDA Breakthrough Device Designation, highlighting the company’s focus on developing a diagnostic approach for a condition in which frequent monitoring of a key biomarker is an important part of long-term disease management. However, the designation does not represent FDA clearance or approval, and PheCheck remains investigational and is not commercially available.
Developing a New Approach to PKU Monitoring
Phenylketonuria is an inherited metabolic disorder in which the body has difficulty processing phenylalanine, an amino acid found in many protein-containing foods. Elevated phenylalanine levels can cause serious health consequences if they are not appropriately managed.
People living with PKU often require long-term monitoring of phenylalanine levels as part of their disease management. Maintaining appropriate Phe levels can involve dietary management, medications and ongoing monitoring, depending on the individual’s clinical circumstances.
Aptatek is developing PheCheck with the aim of making this monitoring process more convenient and responsive by bringing quantitative testing closer to the patient.
The system combines several components into a connected diagnostic platform. It uses DNA aptamer-based sensing technology together with a reusable handheld reader, a single-use test cartridge and a smartphone-connected application.
This architecture is designed to allow users to perform testing outside conventional laboratory settings while also creating a mechanism for collecting and communicating measurement data.
The company believes that rapid access to quantitative Phe measurements could potentially help patients and care teams make more timely decisions as part of routine PKU management.
Aptamer-Based Sensing Technology
A key component of PheCheck is its use of DNA aptamer-based sensing.
Aptamers are short nucleic acid sequences that can be engineered to bind to specific molecular targets. Their ability to recognize particular analytes has made them an area of interest for diagnostic applications and other forms of biomarker detection.
Aptatek is applying this technology to develop a sensing system capable of measuring phenylalanine in blood. The company is combining the assay technology with a reusable reader and disposable testing cartridge to create an integrated diagnostic workflow.
The HomeCheck platform is intended to support decentralized testing, potentially allowing measurements to be performed closer to where patients live rather than requiring every test to be conducted through a centralized laboratory.
For people who need repeated biomarker monitoring, decentralized testing could provide a way to obtain measurements more conveniently and potentially reduce the time between sample collection and access to results.
Aptatek has completed preclinical testing of the investigational PheCheck system, including analytical evaluation against liquid chromatography-mass spectrometry (LC-MS), a reference laboratory methodology commonly used for precise analytical measurements.
The company is now evaluating the system clinically as it works toward generating the evidence required for regulatory review.
Connected Monitoring Through a Smartphone Application
PheCheck is being designed not simply as a point-of-care testing device but as a connected monitoring system.
The reusable handheld reader and disposable cartridge are paired with a smartphone-connected application. The system is intended to capture Phe measurements over time, creating a longitudinal record of results that can potentially help patients and healthcare professionals understand changes in phenylalanine levels.
The platform is also designed to enable data to be securely shared with authorized care teams.
This connected architecture could be particularly relevant for chronic conditions such as PKU, where disease management extends over many years and treatment decisions may benefit from understanding biomarker trends rather than relying only on individual measurements.
By combining testing, data capture and connectivity, Aptatek aims to establish a framework that could eventually support broader applications in decentralized metabolic monitoring.
Financing Supports Clinical Development
The initial financing close provides Aptatek with additional resources to continue clinical development of PheCheck and advance the HomeCheck platform.
Michael Boyce-Jacino, PhD, Chief Executive Officer of Aptatek Biosciences, said the financing will support the company’s efforts to generate clinical evidence for the investigational diagnostic and advance its regulatory strategy.
“People living with PKU manage phenylalanine levels throughout their lives, yet today’s testing process can involve lengthy delays in receiving results,” Boyce-Jacino said.
He added that the financing will support the clinical evaluation of PheCheck and Aptatek’s objective of generating evidence for a potential FDA submission while continuing development of its connected diagnostic platform.
The company expects to complete its ongoing clinical study before year-end. Results from the study are expected to play an important role in Aptatek’s planned regulatory submission.
The clinical study is listed on ClinicalTrials.gov under identifier NCT07551921.
Strategic Support From Canterbury Scientific
Canterbury Scientific, which led the financing alongside Longview Innovation, brings expertise in the in vitro diagnostics sector. The company is a global original equipment manufacturer supplier of in vitro diagnostic controls.
Clive Seymour, Chief Executive Officer of Canterbury Scientific, said Aptatek’s work addresses the broader need to bring biomarker testing closer to patients.
“Aptatek is working to move sophisticated biomarker testing closer to the patient, addressing an important need in conditions where frequent, timely measurement can improve disease management,” Seymour said.
He described PheCheck as an important first application for the HomeCheck platform and noted the potential for the technology to eventually be applied to additional chronic diseases.
The investment therefore provides support not only for the current PKU program but also for Aptatek’s broader objective of developing a decentralized diagnostic platform.
Longview Innovation Invests in Platform Potential
Longview Innovation also participated in the financing, supporting Aptatek’s efforts to develop PheCheck and establish a broader technology infrastructure for home-based biomarker testing.
Jason Smith, Managing Partner of Longview Innovation, said the investment was driven by the company’s technical foundation, the clinical need associated with PKU monitoring and the potential to build a broader decentralized testing platform.
“We invested in Aptatek because of the team’s technical foundation, clear patient need and the opportunity to build a broader platform for decentralized biomarker monitoring,” Smith said.
He described PheCheck as a focused initial application in PKU that could establish infrastructure spanning the diagnostic device, assay and connected data components.
The company’s strategy is therefore centered on using PKU as an initial clinical application while developing capabilities that could potentially be adapted to other chronic diseases requiring regular biomarker measurement.
Potential Expansion Beyond PKU
Although PheCheck is currently focused on phenylalanine monitoring in people with PKU, Aptatek views the HomeCheck platform as having applications beyond a single disease.
The broader concept is based on decentralized biomarker monitoring, in which diagnostic testing can be conducted closer to patients and connected to digital systems that facilitate the management and interpretation of results.
The combination of assay technology, reusable hardware, disposable cartridges and connected software could provide a foundation for additional applications if future development demonstrates that the platform can be adapted to other biomarkers.
Such expansion would require separate development, validation and regulatory evaluation for each application. The potential to support other chronic conditions remains a future opportunity rather than an established clinical application of PheCheck.
For now, Aptatek’s primary focus remains advancing the investigational PKU test through its ongoing clinical study and generating the evidence needed for its planned FDA submission.
Regulatory Pathway Remains Ahead
The FDA Breakthrough Device Designation is an important milestone for PheCheck, but it does not mean that the system has been cleared or approved for clinical use.
The Breakthrough Devices Program is intended to facilitate development and regulatory review of certain medical devices that address serious conditions and for which there is a potential for significant clinical benefit. Designated devices may receive additional interaction with the FDA during development and review.
PheCheck remains an investigational technology. Aptatek must complete its clinical and regulatory activities before the system could potentially become available for routine patient use.
The company’s expected completion of its ongoing clinical study before year-end represents an important next step. The resulting data will be used to inform the planned FDA regulatory submission and provide additional evidence regarding the performance of the diagnostic system.
Advancing Decentralized Metabolic Diagnostics
The financing positions Aptatek to continue development of a diagnostic approach designed to address the practical challenges of frequent metabolic monitoring.
For individuals living with PKU, phenylalanine management is a long-term consideration. A testing system that could provide quantitative measurements at home may have the potential to change how biomarker information is collected and communicated, subject to successful clinical validation and regulatory authorization.
Aptatek’s approach combines biomarker sensing with connected digital infrastructure, creating a system intended to support both measurement and longitudinal data management.
The company’s immediate objective is to advance PheCheck through clinical evaluation and toward an FDA submission. At the same time, Aptatek and its investors are positioning the HomeCheck platform as a potential foundation for broader decentralized diagnostic applications.
With financial support from Canterbury Scientific and Longview Innovation, Aptatek plans to continue clinical development of PheCheck, advance its connected diagnostic technology and evaluate opportunities for future expansion.
The company emphasized that PheCheck remains investigational, has not been cleared or approved by the FDA and is not commercially available. Further clinical and regulatory work will determine the next steps for the technology and its potential role in at-home phenylalanine monitoring for people living with PKU.
About Aptatek Biosciences
Aptatek Biosciences, Inc. is a Columbia University spinout developing connected, aptamer-enabled diagnostic technologies for decentralized metabolic monitoring. Its lead investigational program, PheCheck, is designed for quantitative phenylalanine measurement at home for people living with PKU.